PPD Declares Fourth Quarter Dividend
November 11, 2009 04:05 PM Eastern Time
WILMINGTON, N.C.--(EON: Enhanced Online News)--PPD, Inc. (Nasdaq: PPDI) today announced its board of directors decl dividend for the fourth quarter of 2009 under its annual cash dividend policy. The quarterly cash dividend will equal $0.15 per share for the fourth quarter dividend is December 15, 2009, and the payment date is December 29, 2009. The annual cash dividend polic of future quarterly cash dividends under that policy are subject to the continuing determination by the board of directors that the poli best interests of the company's shareholders and in compliance with applicable laws and agreements.
PPD is a leading global contract research organization providing discovery, development and post-approval services as well as com programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. countries and more than 10,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commit help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics more information, visit our Web site at http://www.ppdi.com.
Except for historical information, all of the statements, expectations and assumptions, including expectations and assumpt payment of future cash dividends under the annual dividend policy, contained in this news release are forward-looking stat involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking state possible that future circumstances might differ from the assumptions on which such statements are based. In addition, othe factors which could cause results to differ materially include the following: risks that we may not continue our dividend pol conditions and outsourcing trends in the pharmaceutical, biotechnology and medical device industries and government-spo sector; success in sales growth; loss of or delay in large contracts; competition within the outsourcing industry; risks associ development and commercialization of drugs, including obtaining regulatory approvals; the ability to attract and retain ke dependence on collaborative relationships; rapid technological advances that make our products and services less competi other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon PPD investor relations department.
Contacts
PPD, Inc. Dan Darazsdi, 910-558-7915 daniel.darazsdi@ppdi.com or Luke Heagle, 910-558-7585 luke.heagle@ppdi.com Permalink: http://eon.businesswire.com/news/eon/20091111006103/en